cagrisema cagrilintide semaglutide phase 3 obesity Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, 2 trial CagriSema vs Tirzepatide: 23% Weight

Description

Combining compounds multiplies the number of potential side effects at play, and stacking unapproved research chemicals without medical supervision carries meaningfully more risk than using a single compound on its own

Which One is Best

Evidence signal Skin and hair research 3 source-backed citations are connected to this page

3 After roughly 18 months, participants lost about 10 percent of body weight, and average total testosterone increased by 18 percent, suggesting that weight reduction from GLP-1 therapy may help reverse obesity-related low testosterone